Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| KR KROSKeros Therapeutics | $11.03+0.7% | $218.7M | 9 assetsPhase 2 | KER-065Phase 2 · Data readout | |
| KR KRROKorro Bio, Inc. | $13.18+1.7% | $194.1M | 4 assetsStage unavailable | No dated catalyst | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $346.58+2.8% |
| $10.26B |
12 assetsPhase 3 |
KB803 (Ophthalmic B-VEC)Phase 3 · Data readout |
| KT KTRAKintara Therapeutics | $2.00-9.9% | — | 3 assetsStage unavailable | No dated catalyst |
| KT KTTAPasithea Therapeutics | $0.54+14.8% | $18.0M | 2 assetsPhase 1 | PAS-004Phase 1 · Data readout |
| KU KURAKura Oncology | $11.89+1.5% | $1.06B | 15 assetsPhase 3 | Ziftomenib + gilteritinibPhase 1 · Data readout |
| KY KYMRKymera Therapeutics | $119.80-1.4% | $9.85B | 12 assetsPhase 2b | KT-579Phase 1 · Data readout |
| KY KYTXKyverna Therapeutics | $8.42+3.6% | $520.7M | 5 assetsPhase 2 | KYV-101Phase 2 · Data readout |
| KZ KZIAKazia Therapeutics | $13.41-1.9% | $153.2M | 7 assetsPhase 1b | Paxalisib (GDC-0084)Phase 1b · Data readout |
| KZ KZRKezar Life Sciences | $7.29+0.0% | $53.9M | 4 assetsStage unavailable | No dated catalyst |
| LA LABPLandos Biopharma | $22.93+0.6% | — | 7 assetsStage unavailable | No dated catalyst |
| LA LADXLadRx Corporation | $0.10+0.0% | $49,509 | 5 assetsStage unavailable | No dated catalyst |
| LB LBPHLongboard Pharmaceuticals | $59.98+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| LC LCTXLineage Cell Therapeutics | $1.08+0.0% | $273.1M | 3 assetsStage unavailable | No dated catalyst |
| LE LEGNLegend Biotech Corporation | $21.82+2.6% | $4.24B | 7 assetsStage unavailable | No dated catalyst |
| LE LENZLENZ Therapeutics, Inc. | $4.68+0.4% | $147.0M | 2 assetsStage unavailable | No dated catalyst |
| LG LGVNLongeveron Inc | $0.84+2.0% | $26.9M | 5 assetsPhase 2b | Lomecel-B (laromestrocel)Phase 2b · Data readout |
| LI LIXTLIXTE Biotechnology Holdings, Inc. | $7.21+0.0% | $125.4M | 3 assetsStage unavailable | No dated catalyst |
| LL LLYEli Lilly & Company | $1255.40+0.9% | $965.26B | 42 assetsApproved | PirtobrutinibPDUFA · Approval decision |
| LM LMNLLiminal BioSciences | $8.50+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| LN LNTHLantheus Holdings | $99.97-0.3% | $6.53B | 17 assetsStage unavailable | No dated catalyst |
| LP LPCNLipocine Inc | $2.09+0.0% | $17.2M | 8 assetsStage unavailable | No dated catalyst |
| LQ LQDALiquidia Technologies | $68.62-3.4% | $6.14B | 2 assetsStage unavailable | No dated catalyst |
| LR LRMRLarimar Therapeutics | $4.18+0.5% | $434.2M | 1 assetsStage unavailable | No dated catalyst |
| LS LSTALisata Therapeutics | $1.55+38.4% | $14.0M | 12 assetsPhase 1/2 | LSTA1 + gemcitabine/nab-paclitaxelPhase 1/2 · Data readout |
| LT LTRNLantern Pharma | $2.34+2.2% | $29.9M | 9 assetsPhase 2 | LP-300Phase 2 · Data readout |
| LU LUMOLumos Pharma | $4.34+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| LV LVTXLava Therapeutics | $1.74+0.0% | $45.8M | 4 assetsStage unavailable | No dated catalyst |
| LX LXEOLexeo Therapeutics | $4.88-3.6% | $400.4M | 3 assetsPhase 3 | LX2020Phase 1/2 · Data readout |
| LX LXRXLexicon Pharmaceuticals Inc | $2.30+5.5% | $1.02B | 6 assetsPhase 3 | ZYNQUISTA™ (sotagliflozin)Phase 3 · Data readout |
| LY LYELLyell Immunopharma | $15.53+1.2% | $380.6M | 5 assetsPhase 3 | Ronde-cel (LYL314)Phase 3 · Data readout |
| LY LYRALyra Therapeutics | $0.01+2400.0% | $17,748 | 2 assetsStage unavailable | No dated catalyst |
| MA MAIAMAIA Biotechnology, Inc. | $1.39+0.7% | $84.5M | 2 assetsStage unavailable | No dated catalyst |
| MA MANEVeradermics | $102.82-2.4% | $4.30B | 2 assetsPhase 3 | Minoxidil (VDPHL01) (Potassium Channel Opener)Phase 3 · Data readout |
| MA MAZEMaze Therapeutics | $29.43+1.7% | $1.63B | 3 assetsPhase 2 | MZE829 (APOL1 Inhibitor)Phase 2 · Data readout |
| MB MBIOMustang Bio Inc | $0.58+2.0% | $4.4M | 10 assetsStage unavailable | No dated catalyst |
| MB MBRXMoleculin Biotech | $0.59+0.4% | $11.6M | 10 assetsPhase 2/3 | No dated catalyst |
| MB MBXMBX Biosciences | $66.33-0.0% | $3.19B | 3 assetsPhase 1 | MBX 4291Phase 1 · Data readout |
| MC MCRBSeres Therapeutics | $4.56-0.2% | $45.8M | 8 assetsPhase 1 | No dated catalyst |
| MD MDGLMadrigal Pharmaceuticals | $516.74-0.5% | $11.94B | 3 assetsPhase 3 | Rezdiffra (Resmetirom) (MGL-3196)Phase 3 · Data readout |